Dashboard
Manage Tickers

PCVX Vaxcyte, Inc.

Nasdaq vaxcyte.com


$ 42.63 $ 0.16 (0.38 %)    

Wednesday, 22-Oct-2025 16:03:30 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 605.51 $ -5.89 (-0.96 %)
DIA $ 465.28 $ -3.44 (-0.73 %)
SPY $ 667.76 $ -3.49 (-0.52 %)
TLT $ 92.21 $ 0.06 (0.07 %)
GLD $ 375.81 $ 0.04 (0.01 %)
$ 42.51
$ 42.87
$ 42.15 x 3
$ 44.20 x 227
$ 42.18 - $ 43.40
$ 27.66 - $ 116.00
1,396,230
na
5.52B
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 02-25-2025 12-31-2024 10-K
4 11-05-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-27-2024 12-31-2023 10-K
8 11-06-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 02-27-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-11-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-29-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

thermo-fisher-launches-four-part-bond-offering-ahead-of-possible-government-shutdown
Thermo Fisher Launches Four-Part Bond Offe...
09/30/2025 15:42:34

Thermo Fisher sells four-part dollar bonds as U.S. investment-grade issuance tops $200 billion, with yields near historic lows ...

vaxcyte-enters-partnership-with-thermo-fisher-scientific-to-secure-additional-us-fill-finish-commercial-manufacturing-for-its-broad-spectrum-pneumococcal-conjugate-vaccines--representing-up-to-1b-in-manufacturing-and-service
Vaxcyte Enters Partnership With Thermo Fis...
09/30/2025 12:44:21

Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced a new agreement with Thermo Fisher Sc...

goldman-sachs-initiates-coverage-on-vaxcyte-with-neutral-rating-announces-price-target-of-38
Goldman Sachs Initiates Coverage On Vaxcyt...
09/12/2025 15:32:12

Goldman Sachs analyst Asad Haider initiates coverage on Vaxcyte (NASDAQ:PCVX) with a Neutral rating and announces Price Tar...

merck-advances-childhood-pneumococcal-care-with-promising-vaccine-data
Merck Advances Childhood Pneumococcal Care...
09/11/2025 14:23:43

Merck's Capvaxive vaccine showed strong immune responses and a comparable safety profile to PPSV23 in high-risk children du...

vaxcyte-advances-study-of-new-vaccine-for-pneumococcal-disease-in-infants-pegtibatinase-maintained-significant-reductions-in-toxic-metabolites
Vaxcyte Advances Study of New Vaccine for ...
09/03/2025 11:33:50

Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankin...

redwire-posts-downbeat-q2-results-joins-tandem-diabetes-care-fortinet-symbotic-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
Redwire Posts Downbeat Q2 Results, Joins T...
08/07/2025 12:14:08

vaxcyte-q2-eps-122-misses-117-estimate
Vaxcyte Q2 EPS $(1.22) Misses $(1.17) Esti...
08/06/2025 20:54:57

Core News & Articles
FDA's Vinayak Prasad Says No High-Quality ...
05/20/2025 17:20:20

https://x.com/US_FDA/status/1924871996216951112 

Core News & Articles
'US FDA Advisers To Consider If New COVID ...
05/20/2025 15:20:19

https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-advisers-consider-if

vaxcyte-q1-eps-104-beats-111-estimate
Vaxcyte Q1 EPS $(1.04) Beats $(1.11) Estimate
05/07/2025 20:48:19

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.04) per share which beat the analyst consensus estimate of $(1.11) by 6....

cantor-fitzgerald-initiates-coverage-on-vaxcyte-with-overweight-rating
Cantor Fitzgerald Initiates Coverage On Va...
04/22/2025 11:46:20

Cantor Fitzgerald analyst Carter Gould initiates coverage on Vaxcyte (NASDAQ:PCVX) with a Overweight rating.

needham-reiterates-buy-on-vaxcyte-maintains-90-price-target
Needham Reiterates Buy on Vaxcyte, Maintai...
04/08/2025 12:40:25

Needham analyst Joseph Stringer reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $90 price target.

goldman-sachs-maintains-buy-on-vaxcyte-lowers-price-target-to-100
Goldman Sachs Maintains Buy on Vaxcyte, Lo...
04/01/2025 16:51:03

Goldman Sachs analyst Chris Shibutani maintains Vaxcyte (NASDAQ:PCVX) with a Buy and lowers the price target from $138 to $100.

b-of-a-securities-maintains-buy-on-vaxcyte-lowers-price-target-to-137
B of A Securities Maintains Buy on Vaxcyte...
04/01/2025 13:20:54

B of A Securities analyst Jason Gerberry maintains Vaxcyte (NASDAQ:PCVX) with a Buy and lowers the price target from $157 to...

ulta-beauty-to-rally-over-15-here-are-10-top-analyst-forecasts-for-tuesday
Ulta Beauty To Rally Over 15%? Here Are 10...
04/01/2025 12:44:10

needham-maintains-buy-on-vaxcyte-lowers-price-target-to-90
Needham Maintains Buy on Vaxcyte, Lowers P...
04/01/2025 10:02:06

Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:PCVX) with a Buy and lowers the price target from $140 to $90.

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
03/31/2025 17:05:39

vaxcyte-plans-to-drop-developing-one-pneumococcal-conjugate-vaccine
Vaxcyte Plans To Drop Developing One Pneum...
03/31/2025 12:56:13

Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious vaccin...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
03/31/2025 12:05:38

vaxcyte-announced-topline-results-from-its-phase-2-dose-finding-study-evaluating-the-safety-tolerability-and-immunogenicity-of-vax-24-to-prevent-invasive-pneumococcal-disease-compared-to-prevnar-20-in-healthy-infants
Vaxcyte Announced Topline Results From Its...
03/31/2025 11:21:02

At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20 (PCV...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION